Investing.com – Mylan (NASDAQ:MYL) Q3 EPS estimate $1.46% on yoy rise in revenues to $3.14 bn.
Earnings to reflect $465 mn settlement of EpiPen allergy injector pricing storm.
Mylan to report earnings on Wednesday after the market closes.
Political pressure on drug prices clouds share price prospects for Mylan and the sector.
Hillary Clinton campaigned against the pricing of EpiPen.
NASDAQ Biotechnology Index down over 26% since the beginning of 2016.